查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1386389

次單位疫苗市場報告：2030 年趨勢、預測與競爭分析

Subunit Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

次單位疫苗趨勢和預測

至2030年，全球次單位疫苗市場預計將達到24億美元，2024年至2030年的複合年成長率為10.5%。該市場的主要促進因素是免疫接種和高安全性疫苗需求的增加以及感染疾病流行的增加。全球次單位疫苗市場前景看好，感染疾病、白喉、破傷風、百日咳（DTP）、HPV、麻疹、腮腺炎和德國德國麻疹（MMR）市場充滿機會。

次單位疫苗市場洞察

Lucintel 預測，由於蛋白質抗原次單位疫苗的廣泛可用性和易於採用，蛋白質將繼續佔據很大一部分。

由於感染疾病高發，北美仍然是最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1. 區隔市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個區隔市場將以更快的速度成長？為什麼？
  • Q.3.哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要課題和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去五年發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章執行摘要

第2章全球次單位疫苗市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與課題

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球次單位疫苗市場趨勢（2018-2023）與預測（2024-2030）
  • 依產品類型分類的全球次單位疫苗市場
    • 蛋白質抗原
    • 多醣體抗原
  • 依疾病分類的全球次單位疫苗市場
    • 感染疾病
    • 白喉
    • 破傷風和百日咳 (DTP)
    • HPV
    • 麻疹
    • 流行性腮腺炎和德國麻疹(MMR)
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球次單位疫苗市場（依地區）
  • 北美次單位疫苗市場
  • 歐洲次單位疫苗市場
  • 亞太次單位疫苗市場
  • 其他區域次單位疫苗市場

第5章競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 依產品類型分類的全球次單位疫苗市場成長機會
    • 全球次單位疫苗市場依疾病分類的成長機會
    • 全球次單位疫苗市場成長機會（依地區）
  • 全球次單位疫苗市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球次單位疫苗市場產能擴張
    • 全球次單位疫苗市場的合併、收購和合資企業
    • 認證和許可

第7章主要企業概況

  • GE Healthcare Life Sciences
  • GlaxoSmithKline
  • Merck
  • Reber Genetics
  • Sanofi
  • Algenex
  • Astellas Pharma
簡介目錄

Subunit Vaccine Trends and Forecast

The future of the global subunit vaccine market looks promising with opportunities in the infectious disease, diphtheria, tetanus and pertussis (DTP), HPV, measles, and mumps & rubella (MMR) markets. The global subunit vaccine market is expected to reach an estimated $2.4 billion by 2030 with a CAGR of 10.5% from 2024 to 2030. The major drivers for this market are rising demand for immunization and better safety vaccines and growing prevalence of infectious diseases.

A more than 150-page report is developed to help in your business decisions.

Subunit Vaccine by Segment

The study includes a forecast for the global subunit vaccine by product type, disease, and region.

Subunit Vaccine Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

  • Protein Antigen
  • Polysaccharide Antigen

Subunit Vaccine Market by Disease [Shipment Analysis by Value from 2018 to 2030]:

  • Infectious Disease
  • Diphtheria
  • Tetanus and Pertussis (DTP)
  • HPV
  • Measles
  • Mumps and Rubella (MMR)
  • Others

Subunit Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Subunit Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies subunit vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the subunit vaccine companies profiled in this report include-

  • GE Healthcare Life Sciences
  • GlaxoSmithKline
  • Merck
  • Reber Genetics
  • Sanofi
  • Algenex
  • Astellas Pharma

Subunit Vaccine Market Insights

Lucintel forecasts that protein will remain the larger segment due to its widespread availability and adoptability of protein antigen subunit vaccines.

North America will remain the largest region due to the high prevalence of infectious diseases in this region.

Features of the Global Subunit Vaccine Market

Market Size Estimates: Subunit vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Subunit vaccine market size by product type, disease, and region in terms of value ($B).

Regional Analysis: Subunit vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, diseases, and regions for the subunit vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the subunit vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the subunit vaccine market size?

Answer: The global subunit vaccine market is expected to reach an estimated $2.4 billion by 2030.

Q.2 What is the growth forecast for subunit vaccine market?

Answer: The global subunit vaccine market is expected to grow with a CAGR of 10.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the subunit vaccine market?

Answer: The major drivers for this market are rising demand for immunization and better safety vaccines and growing prevalence of infectious diseases.

Q4. What are the major segments for subunit vaccine market?

Answer: The future of the subunit vaccine market looks promising with opportunities in the infectious disease, diphtheria, tetanus and pertussis (DTP), HPV, measles, and mumps & rubella (MMR) markets.

Q5. Who are the key subunit vaccine market companies?

Answer: Some of the key subunit vaccine companies are as follows:

  • GE Healthcare Life Sciences
  • GlaxoSmithKline
  • Merck
  • Reber Genetics
  • Sanofi
  • Algenex
  • Astellas Pharma

Q6. Which subunit vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that protein will remain the larger segment due to its widespread availability and adoptability of protein antigen subunit vaccines.

Q7. In subunit vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region due to the high prevalence of infectious diseases in this region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the subunit vaccine market by product type (protein antigen and polysaccharide antigen), disease (infectious disease, diphtheria, tetanus and pertussis (DTP), HPV, measles, mumps and rubella (MMR), and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Subunit Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Subunit Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Subunit Vaccine Market by Product Type
    • 3.3.1: Protein Antigen
    • 3.3.2: Polysaccharide Antigen
  • 3.4: Global Subunit Vaccine Market by Disease
    • 3.4.1: Infectious Disease
    • 3.4.2: Diphtheria
    • 3.4.3: Tetanus and Pertussis (DTP)
    • 3.4.4: HPV
    • 3.4.5: Measles
    • 3.4.6: Mumps and Rubella (MMR)
    • 3.4.7: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Subunit Vaccine Market by Region
  • 4.2: North American Subunit Vaccine Market
    • 4.2.2: North American Subunit Vaccine Market by Disease: Infectious Disease, Diphtheria, Tetanus and Pertussis (DTP), HPV, Measles, Mumps and Rubella (MMR), and Others
  • 4.3: European Subunit Vaccine Market
    • 4.3.1: European Subunit Vaccine Market by Product Type: Protein Antigen and Polysaccharide Antigen
    • 4.3.2: European Subunit Vaccine Market by Disease: Infectious Disease, Diphtheria, Tetanus and Pertussis (DTP), HPV, Measles, Mumps and Rubella (MMR), and Others
  • 4.4: APAC Subunit Vaccine Market
    • 4.4.1: APAC Subunit Vaccine Market by Product Type: Protein Antigen and Polysaccharide Antigen
    • 4.4.2: APAC Subunit Vaccine Market by Disease: Infectious Disease, Diphtheria, Tetanus and Pertussis (DTP), HPV, Measles, Mumps and Rubella (MMR), and Others
  • 4.5: ROW Subunit Vaccine Market
    • 4.5.1: ROW Subunit Vaccine Market by Product Type: Protein Antigen and Polysaccharide Antigen
    • 4.5.2: ROW Subunit Vaccine Market by Disease: Infectious Disease, Diphtheria, Tetanus and Pertussis (DTP), HPV, Measles, Mumps and Rubella (MMR), and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Subunit Vaccine Market by Product Type
    • 6.1.2: Growth Opportunities for the Global Subunit Vaccine Market by Disease
    • 6.1.3: Growth Opportunities for the Global Subunit Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Subunit Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Subunit Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Subunit Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: GE Healthcare Life Sciences
  • 7.2: GlaxoSmithKline
  • 7.3: Merck
  • 7.4: Reber Genetics
  • 7.5: Sanofi
  • 7.6: Algenex
  • 7.7: Astellas Pharma